


INFORMATION DISCLOSURE CITATION

Atty. Docket No. 5273-90	Appln. No. 10/647,234
Applicant Koichiro YAMADA et al.	
Filing Date August 26, 2003	Group: Not yet assigned - 1629



U.S. PATENT DOCUMENTS

Examiner Initial*	Document Number	Issue Date	Name	Class	Sub Class	Filing Date If Appropriate
TC	6,136,810	24 Oct 2000	Takayama et al.	514	258	
	5,817,670	6 Oct 1998	Takayama et al.	514	300	
	5,733,914	31 Mar 1998	Blankley et al.	514	258	
	5,693,652	2 Dec 1997	Takase et al.	514	322	
	5,466,692	14 Nov 1995	Ellingboe	514	258	
	4,229,456	21 Oct 1980	Bolhofer et al.	424	256	
	4,060,615	29 Nov 1977	Matier et al.	424	251	

FOREIGN PATENT DOCUMENTS

	Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No
tc	WO 96/16644	6 June 1996	WIPO			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)


tc	Bolhofer, W., et al., "Inhibition of Gastric Acid Secretion by 1,8-Naphthyridin-2(1H)-ones," J. of Med. Chem., Vol. 22, No. 3, pp. 301-306 (1979).

Examiner <i>Don McKie</i>	Date Considered <i>2/15/05</i>
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
Form PTO 1449	Patent and Trademark Office - U.S. Department of Commerce

627626_1.DOC

INFORMATION DISCLOSURE CITATION

Atty. Docket No. 5273-90	Serial No. 10/647,234
Applicant Koichiro YAMADA et al.	
Filing Date August 26, 20003	Group: Not yet assigned



U.S. PATENT DOCUMENTS

Examiner Initial*	Document Number	Issue Date	Name	Class	Sub Class	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

	Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No
✓	EP 0722936	24 July 1996	Europe			
✓	AU 199955977 A1	4 May 2000	Australia			
✓	DE 2064 096	6 July 1972	Germany			Abstract


OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

✓	Vermulapalli, S., et al., "Sildenafil relaxes rabbit clitoral corpus cavernosum," Life Sciences, Vol. 67, pp. 23-29 (2000).
	Watkins, C., et al., "Insulin restores neuronal nitric oxide synthase expression and function that is lost in diabetic gastropathy," The Journal of Clinical Investigation, Vol. 106, No. 3, pp. 373-384 (2000).
	Bortolotti, M., et al., "Effects of Sildenafil on Esophageal Motility of Patients with Idiopathic Achalasia," Gastroenterology, Vol. 118, pp. 253-257 (2000).
	Mule F., et al., "Tonic Inhibitory action by nitric oxide on spontaneous mechanical activity in rat proximal colon: involvement of cyclic GMP and apamin-sensitive K ⁺ channels," British Journal of Pharmacology, Vol. 127, pp. 514-520 (1999).
	Turner, N., et al., "Pulmonary effects of type V cyclic GMP specific phosphodiesterase inhibition in the anesthetized guinea-pig," British Journal of Pharmacology, Vol. 111, pp. 1198-1204 (1994).
	Bakre M., et al., "Expression and Regulation of the cGMP-Binding, cGMP-Specific Phosphodiesterase (PDE5) in Colonic Epithelial Cells: Role in the Induction of Cellular Refractoriness to the Heat-Stable Enterotoxin Peptide," Journal of Cellular Biochemistry, Vol. 77, pp. 159-167 (2000).
✓	Boolell, M., et al., "A new oral treatment for erectile dysfunction. A Double-blind, placebo controlled crossover study demonstrating dose response with rigiscan and efficacy with outpatient diary," The Journal of Urology, Supplement, Vol. 155, No. 5, p. 495A 739 (1996).

Don McQu...

2/18/01

INFORMATION DISCLOSURE CITATION

Atty. Docket No. 5273-90	Serial No. 10/647,234	
Applicant Koichiro YAMADA et al.		
Filing Date August 26, 20003	Group: <u>1624</u> Not yet assigned	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
<i>TCu</i>	Terrett, N., et al., "Sildenafil (Viagra™), a potent and selective inhibitor of type 5 CGMP phosphodiesterase with utility for the treatment of male erectile dysfunction," Bioorganic & Medicinal Chemistry Letters, Vol. 6, No. 15, pp. 1819-1824 (1996).
	Ballard, S., et al., "Sildenafil, a potent selective inhibitor of type 5 phosphodiesterase, enhances nitric oxide-dependent relaxation of rabbit corpus cavernosum," British Journal of Pharmacology, Proceedings Supplement, Vol. 118, 153P (1996).
	Goldstein, I., et al., "Oral sildenafil in the treatment of erectile dysfunction," The New England Journal of Medicine, Vol. 338, No. 20, p. 1397-1404 (1998).
	Goldenberg, M., "Safety and Efficacy of Sildenafil Citrate in the Treatment of Male Erectile Dysfunction," Clinical Therapeutics, Vol. 20, No. 6, pp. 1033-1048 (1998).
	Morales, A., et al., "Clinical safety of oral sildenafil citrate (VIAGRA™) in the treatment of erectile dysfunction," International Journal of Impotence Research, Vol. 10, No. 2, pp. 69-73 (1998).
	Estrade, M., et al., "Effect of a cGMP-specific phosphodiesterase inhibitor on retinal function," European Journal of Pharmacology, Vol. 352, pp. 157-163 (1998).
	Todd, C., et al., "Sulfilimines Derived from Sulfanilamide," Journal of American Chemical Society, Vol. 65, pp. 350-355 (1943).
	Grohe, K., et al., "Synthese und Reaktionen von 2,4-Dichlorpyrimidin-5-carbon-saurestem," Liebigs Ann. Chem., pp. 1025-1035 (1973).

Examiner <i>Don McPh</i>	Date Considered <i>2/18/05</i>
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
Form PTO-1449	Patent and Trademark Office - U.S. Department of Commerce

628022_1